Biopharmaceutical
Upcoming Earnings
Therapy

Celgene

$89.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (0.39%) Today
$0.00 (0.00%) As of 4:25 PM EDT after-hours

Why Robinhood?

You can buy or sell Celgene and other stocks, options, ETFs, and crypto commission-free!

About CELG

Celgene Corporation Common Stock, also called Celgene, is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. Read More The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Employees
8,852
Headquarters
Summit, New Jersey
Founded
1986
Market Cap
63.06B
Price-Earnings Ratio
13.60
Dividend Yield
0.00
Average Volume
3.43M
High Today
$89.96
Low Today
$89.09
Open Price
$89.42
Volume
5.99M
52 Week High
$98.97
52 Week Low
$58.59

Collections

Biopharmaceutical
Upcoming Earnings
Therapy
Health
Medical
Cancer Prevention
Biotechnology
Pharmaceutical

CELG News

MarketWatchJul 22

Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect

900
Yahoo FinanceJun 25

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

897
Yahoo FinanceJun 24

Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative

231

CELG Earnings

$1.92
$2.13
$2.34
$2.55
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 25, After Hours

Popular Stocks

More CELG News

Wall Street JournalJun 24

Antitrust Concerns Delay Bristol-Myers’ $74 Billion Merger With Celgene

346
ReutersJun 24

US STOCKS-Wall St flat as healthcare losses limit tech gains

34
CNBCJun 24

Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment

148
BloombergJun 24

Bristol-Myers Will Divest Celgene Blockbuster to Close Deal

14
ReutersJun 24

Bristol-Myers plans to divest Celgene's psoriasis drug

293
MarketWatchJun 24

Bristol-Myers to shed psoriasis drug to win approval for Celgene deal

14
Yahoo FinanceJun 24

Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

9
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.